|
Quality improvement for CKD patients includes:
-
Annual testing to detect the rate of kidney failure due to diabetes
-
Slowing the progression of disease in hypertensive
individuals with diabetes through the use of Angiotensin Converting Enzyme (ACE) inhibitors and/or
Angiotensin Receptor Blocker (ARB) agents
-
Arteriovenous fistula (AV Fistula) placement and maturation (as a first choice
for arteriovenous access where medically appropriate) for individuals who elect
hemodialysis as their treatment option for kidney failure
Listed below are some of the activities that the QIOs' CKD Partners are engaged
in. The Pilot QIOs would be grateful if you could assist with any or all of the
following:
-
Provide an endorsement letter to promote the project
-
Use existing communication vehicles including e-mails, newsletters, journals,
websites, etc. to promote the project by running QIO Support Center (QIOSC)
identified articles
-
Share educational tools and opportunities
-
Inform the QIOSC of any events that may offer cross-promotional activities
-
Promote the project at conferences, allow the project to exhibit at events,
etc.
For more specific information along with tools and resources, please visit
MedQIC or contact Robin Weil, MSHA, RN, CPHQ, Prevention QIOSC Director
at rweil@vaqio.sdps.org.
Click on the state markers below to visit the CKD website for each state
participating in this initiative.
|